PDS Biotechnology Corporation, based in Florham Park, New Jersey, is making headlines for spearheading the development of multifunctional cancer immunotherapies. Founded in 2005, the clinical-stage biopharmaceutical company's standout product candidate is PDS0101 (HPV16), which has entered Phase II clinical trials and holds promise as a first-line treatment for recurrent/metastatic head and neck cancer, in addition to human papillomavirus associated malignancies. But that's not all: PDS Biotechnology Corporation is also testing a range of preclinical product candidates including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for breast and prostate cancers, PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers, and PDS0104 for melanoma treatment comprised of Tyrosinase-related protein 2. Looking beyond cancer treatment, the company is also investigating vaccines for various diseases, such as PDS0201 for tuberculosis, PDS0202 as an influenza vaccine candidate, and PDS0203 as a vaccine for the prevention of COVID-19. To further accelerate its progress, PDS Biotechnology Corporation has forged license and collaboration agreements with some of the leading organizations in the field including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. Overall, PDS Biotechnology Corporation's dedication to pioneering cutting-edge medical solutions is making a significant impact in the healthcare industry.
PDS Biotechnology's ticker is PDSB
The company's shares trade on the NASDAQ stock exchange
They are based in Princeton, New Jersey
There are 11-50 employees working at PDS Biotechnology
It is pdsbiotech.com/about/about-us
PDS Biotechnology is in the Healthcare sector
PDS Biotechnology is in the Biotechnology industry
The following five companies are PDS Biotechnology's industry peers: